Optimization of a cyclic peptide inhibitor of ser/thr phosphatase PPM1D (Wip1)

Biochemistry

Volumn 50, Issue 21, 2011, Pages 4537-4549

  Hayashi, Ryo ^a   Tanoue, Kan ^a   Durell, Stewart R ^a   Chatterjee, Deb K ^b   Jenkins, Lisa M Miller ^a   Appella, Daniel H ^c   Appella, Ettore ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC RINGS; BINDING MODELS; CATALYTIC SITES; CELLULAR STRESS RESPONSE; CYCLIC PEPTIDES; CYCLIC-PEPTIDE INHIBITORS; DEPHOSPHORYLATES; DNA DAMAGES; HUMAN CANCER; INHIBITORY ACTIVITY; MUTAGENESIS EXPERIMENT; NEGATIVE CHARGE; NEW MODEL; NEW STRATEGY; P38 MAPK; SPECIFIC INTERACTION; SUBSTRATE SPECIFICITY; THERAPEUTIC INTERVENTION; THIOETHERS; WILD TYPES;

DISEASES; OPTIMIZATION; PHOSPHATASES; SUBSTRATES;

PEPTIDES;

PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PPM1D PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHIRALITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN STRUCTURE; REACTION OPTIMIZATION;

AMINO ACID SEQUENCE; BASE SEQUENCE; CIRCULAR DICHROISM; DNA PRIMERS; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; PHOSPHOPROTEIN PHOSPHATASES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79958082113     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi101949t     Document Type: Article

References (55)

1. Alonso, A., Sassing, J., Bottini, N., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., and Mustelin, T. (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699-711. (Pubitemid 38748887)
2. Cohen, P. T. (2002) Protein phosphatase 1: Targeted in many directions. J. Cell Sci. 115, 241-256. (Pubitemid 34145174)
3. Andersen, J. N., Jansen, P. G., Echwald, S. M., Mortensen, O. H., Fukada, T., del Vecchio, R., Tonks, N. K., and Moller, N. P. (2004) A genomic perspective on protein tyrosine phosphatases: Gene structure, pseudogenes, and genetic disease linkage. FASEB J. 18, 8-30. (Pubitemid 38076462)
4. Moorhead, G. B., Trinkle-Mulcahy, L., and Ulke-Lemee, A. (2007) Emerging roles of nuclear protein phosphatases. Nat. Rev. Mol. Cell Biol. 8, 234-244.
5. Gallego, M., and Virshup, D. M. (2005) Protein serine/threonine phosphatases: Life, death, and sleeping. Curr. Opin. Cell Biol. 17, 197-202. (Pubitemid 40380944)
6. Fiscella, M., Zhang, H., Fan, S., Sakaguchi, K., Shen, S., Mercer, W. E., Vande Woude, G. F., O'Connor, P. M., and Appella, E. (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 94, 6048-6053. (Pubitemid 27270633)
7. Lu, X., Nguyen, T. A., Moon, S. H., Darlington, Y., Sommer, M., and Donehower, L. A. (2008) The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27, 123-135.
8. Takekawa, M., Adachi, M., Nakahata, A., Nakayama, I., Itoh, F., Tsukuda, H., Taya, Y., and Imai, K. (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 19, 6517-6526.
9. Lu, X., Nannenga, B., and Donehower, L. A. (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19, 1162-1174. (Pubitemid 40696183)
10. Fujimoto, H., Onishi, N., Kato, N., Takekawa, M., Xu, X. Z., Kosugi, A., Kondo, T., Imamura, M., Oishi, I., Yoda, A., and Minami, Y. (2006) Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13, 1170-1180. (Pubitemid 43905597)
11. Yoda, A., Xu, X. Z., Onishi, N., Toyoshima, K., Fujimoto, H., Kato, N., Oishi, I., Kondo, T., and Minami, Y. (2006) Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J. Biol. Chem. 281, 24847-24862. (Pubitemid 44274257)
12. Oliva-Trastoy, M., Berthonaud, V., Chevalier, A., Ducrot, C., Marsolier-Kergoat, M. C., Mann, C., and Leteurtre, F. (2007) The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 26, 1449-1458. (Pubitemid 46340814)
13. Shreeram, S., Demidov, O. N., Hee, W. K., Yamaguchi, H., Onishi, N., Kek, C., Timofeev, O. N., Dudgeon, C., Fornace, A. J., Anderson, C. W., Minami, Y., Appella, E., and Bulavin, D. V. (2006) Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol. Cell 23, 757-764. (Pubitemid 44308587)
14. Li, J., Yang, Y., Peng, Y., Austin, R. J., van Eyndhoven, W. G., Nguyen, K. C., Gabriele, T., McCurrach, M. E., Marks, J. R., Hoey, T., Lowe, S. W., and Powers, S. (2002) Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet. 31, 133-134.
15. Sinclair, C. S., Rowley, M., Naderi, A., and Couch, F. J. (2003) The 17q23 amplicon and breast cancer. Breast Cancer Res. Treat. 78, 313-322. (Pubitemid 36543211)
16. Harrison, M., Li, J., Degenhardt, Y., Hoey, T., and Powers, S. (2004) Wip1-deficient mice are resistant to common cancer genes. Trends Mol. Med. 10, 359-361. (Pubitemid 39061135)
17. Saito-Ohara, F., Imoto, I., Inoue, J., Hosoi, H., Nakagawara, A., Sugimoto, T., and Inazawa, J. (2003) PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63, 1876-1883. (Pubitemid 36460852)
18. Ehrbrecht, A., Muller, U., Wolter, M., Hoischen, A., Koch, A., Radlwimmer, B., Actor, B., Mincheva, A., Pietsch, T., Lichter, P., Reifenberger, G., and Weber, R. G. (2006) Comprehensive genomic analysis of desmoplastic medulloblastomas: Identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 208, 554-563. (Pubitemid 43329342)
19. Hirasawa, A., Saito-Ohara, F., Inoue, J., Aoki, D., Susumu, N., Yokoyama, T., Nozawa, S., Inazawa, J., and Imoto, I. (2003) Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin. Cancer Res. 9, 1995-2004. (Pubitemid 36687618)
20. Loukopoulos, P., Shibata, T., Katoh, H., Kokubu, A., Sakamoto, M., Yamazaki, K., Kosuge, T., Kanai, Y., Hosoda, F., Imoto, I., Ohki, M., Inazawa, J., and Hirohashi, S. (2007) Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome. Cancer Sci. 98, 392-400. (Pubitemid 46195611)
21. Bulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., Appella, E., and Fornace, A. J. J. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)- p19(Arf) pathway. Nat. Genet. 36, 343-350. (Pubitemid 38437256)
22. Yamaguchi, H., Minopoli, G., Demidov, O. N., Chatterjee, D. K., Anderson, C. W., Durell, S. R., and Appella, E. (2005) Substrate specificity of the human protein phosphatase 2Cδ, Wip1. Biochemistry 44, 5285-5294. (Pubitemid 40489968)
23. Yamaguchi, H., Durell, S. R., Chatterjee, D. K., Anderson, C. W., and Appella, E. (2007) The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. Biochemistry 46, 12594-12603. (Pubitemid 350064221)
24. Yamaguchi, H., Durell, S. R., Feng, H., Bai, Y., Anderson, C. W., and Appella, E. (2006) Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cδ, Wip1. Biochemistry 45, 13193-13202. (Pubitemid 44707680)
25. Das, A. K., Helps, N. R., Cohen, P. T., and Barford, D. (1996) Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 Å resolution. EMBO J. 15, 6798-6809.
26. Chuman, Y., Yagi, H., Fukuda, T., Nomura, T., Matsukizono, M., Shimohigashi, Y., and Sakaguchi, K. (2008) Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D. Protein Pept. Lett. 15, 938-948.
27. Pullen, K. E., Ng, H. L., Sung, P. Y., Good, M. C., Smith, S. M., and Alber, T. (2004) An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-Family Ser/Thr protein phosphatase. Structure 12, 1947-1954. (Pubitemid 39469392)
28. Bellinzoni, M., Wehenkel, A., Shepard, W., and Alzari, P. M. (2007) Insights into the catalytic mechanism of PPM Ser/Thr phosphatases from the atomic resolution structures of a mycobacterial enzyme. Structure 15, 863-872. (Pubitemid 47053886)
29. Wehenkel, A., Bellinzoni, M., Schaeffer, F., Villarino, A., and Alzari, P. M. (2007) Structural and binding studies of the three-metal center in two mycobacterial PPM Ser/Thr protein phosphatases. J. Mol. Biol. 374, 890-898. (Pubitemid 350052094)
30. Rantanen, M. K., Lehtio, L., Rajagopal, L., Rubens, C. E., and Goldman, A. (2007) Structure of Streptococcus agalactiae serine/threonine phosphatase. The subdomain conformation is coupled to the binding of a third metal ion. FEBS J. 274, 3128-3137. (Pubitemid 46849094)
31. Almo, S. C., Bonanno, J. B., Sauder, J. M., Emtage, S., Dilorenzo, T. P., Malashkevich, V., Wasserman, S. R., Swaminathan, S., Eswaramoorthy, S., Agarwal, R., Kumaran, D., Madegowda, M., Ragumani, S., Patskovsky, Y., Alvarado, J., Ramagopal, U. A., Faber- Barata, J., Chance, M. R., Sali, A., Fiser, A., Zhang, Z. Y., Lawrence, D. S., and Burley, S. K. (2007) Structural genomics of protein phosphatases. J. Struct. Funct. Genomics 8, 121-140. (Pubitemid 50007113)
32. Schlicker, C., Fokina, O., Kloft, N., Grune, T., Becker, S., Sheldrick, G. M., and Forchhammer, K. (2008) Structural analysis of the PP2C phosphatase tPphA from Thermosynechococcus elongatus: A flexible flap subdomain controls access to the catalytic site. J. Mol. Biol. 376, 570-581.
33. Shi, Y. (2009) Serine/threonine phosphatases: Mechanism through structure. Cell 139, 468-484.
34. Lapatsanis, L., Milias, G., Froussios, K., and Kolovos, M. (1983) Synthesis of N-2,2,2-(Trichloroethoxycarbonyl)-L-Amino Acids and N-(9- Fluorenylmethoxycarbonyl)-L-Amino Acids Involving Succinimidoxy Anion as a Leaving Group in Amino-Acid Protection. Synthesis, 671-673.
35. Janssen, P. S. L., Vannispen, J. W., Melgers, P. A. T. A., Vandenbogaart, H. W. M., Hamelinck, R. L. A. E., and Goverde, B. C. (1986) Hplc Analysis of Phenylthiocarbamyl (Ptc) Amino-Acids. 1. Evaluation and Optimization of the Procedure. Chromatographia 22, 345-350.
36. Janssen, P. S. L., Vannispen, J. W., Melgers, P. A. T. A., Vandenbogaart, H. W. M., Vanaalst, G. W. M., and Goverde, B. C. (1986) Hplc Analysis of Phenylthiocarbamyl (Ptc) Amino-Acids. 2. Application in the Analysis of (Poly)Peptides. Chromatographia 22, 351-357.
37. Jackson, J. L., and Young, M. R. (2003) Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants. Clin. Exp. Metastasis 20, 357-364. (Pubitemid 36745664)
38. Brooks, B. R., Brooks, C. L., III, Mackerell, A. D. J., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., Caflisch, A., Caves, L., Cui, Q., Dinner, A. R., Feig, M., Fischer, S., Gao, J., Hodoscek, M., Im, W., Kuczera, K., Lazaridis, T., Ma, J., Ovchinnikov, V., Paci, E., Pastor, R. W., Post, C. B., Pu, J. Z., Schaefer, M., Tidor, B., Venable, R. M., Woodcock, H. L., Wu, X., Yang, W., York, D. M., and Karplus, M. (2009) CHARMM: The biomolecular simulation program. J. Comput. Chem. 30, 1545-1614.
39. MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph- McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F. T. K., Mattos, C., Michnick, S., Ngo, T., Nguyen, D. T., Prodhom, B., Reiher, W. E., Roux, B., Schlenkrich, M., Smith, J. C., Stote, R., Straub, J., Watanabe, M., Wiorkiewicz-Kuczera, J., Yin, D., and Karplus, M. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586-3616. (Pubitemid 128576688)
40. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. Nucleic Acids Res. 28, 235-242. (Pubitemid 30047768)
41. Gibrat, J. F., Madej, T., and Bryant, S. H. (1996) Surprising similarities in structure comparison. Curr. Opin. Struct. Biol. 6, 377-385. (Pubitemid 26197439)
42. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera: A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612.
43. Bang, J., Yamaguchi, H., Durell, S. R., Appella, E., and Appella, D. H. (2008) A small molecular scaffold for selective inhibition of Wip1 phosphatase. ChemMedChem 3, 230-232.
44. McNemar, C., Snow, M. E., Windsor, W. T., Prongay, A., Mui, P., Zhang, R., Durkin, J., Le, H. V., and Weber, P. C. (1997) Thermodynamic and structural analysis of phosphotyrosine polypeptide binding to Grb2-SH2. Biochemistry 36, 10006-10014. (Pubitemid 27357708)
45. Apostoz, I., Kuciel, R., Wasylewska, E., and Ostrowski, W. S. (1985) Phosphotyrosine as a substrate of acid and alkaline phosphatases. Acta Biochim. Pol. 32, 187-197. (Pubitemid 16233797)
46. Belova, G. I., Demidov, O. N., Fornace, A. J. J., and Bulavin, D. V. (2005) Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol. Ther. 4, 1154-1158. (Pubitemid 41598573)
47. Rayter, S., Elliott, R., Travers, J., Rowlands, M. G., Richardson, T. B., Boxall, K., Jones, K., Linardopoulos, S., Workman, P., Aherne, W., Lord, C. J., and Ashworth, A. (2008) A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 27, 1036-1044. (Pubitemid 351253192)
48. Rye, C. S., and Baell, J. B. (2005) Phosphate isosteres in medicinal chemistry. Curr. Med. Chem. 12, 3127-3141. (Pubitemid 41749255)
49. Ruoslahti, E., Bhatia, S. N., and Sailor, M. J. (2010) Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188, 759-768.
50. Heidel, J. D., and Davis, M. E. (2011) Clinical developments in nanotechnology for cancer therapy. Pharm. Res. 28, 187-199.
51. Franzen, S. (2011) A comparison of peptide and folate receptor targeting of cancer cells: From single agent to nanoparticle. Expert Opin. Drug Delivery 8, 281-298.
52. Falciani, C., Accardo, A., Brunetti, J., Tesauro, D., Lelli, B., Pini, A., Bracci, L., and Morelli, G. (2011) Target-Selective Drug Delivery through Liposomes Labeled with Oligobranched Neurotensin Peptides. ChemMedChem 6, 678-685.
53. Patel, L. N., Zaro, J. L., and Shen, W. (2007) Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm. Res. 24, 1977-1992. (Pubitemid 47493563)
54. Hansen, M., Kilk, K., and Langel, U. (2008) Predicting cellpenetrating peptides. Adv. Drug Delivery Rev. 60, 572-579.
55. Stewart, K. M., Horton, K. L., and Kelley, S. O. (2008) Cellpenetrating peptides as delivery vehicles for biology and medicine. Org. Biomol. Chem. 6, 2242-2255. (Pubitemid 351863664)